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Abstract
Introduction
According to DynaMed Plus (2018), “Anxiety is characterized by 
chronic, unfocused, excessive worry and stress associated with clinically 
significant distress and functional impairment, often accompanied by 
insomnia, restlessness, muscle tension, and concentration problems.” 
Anxiety affects approximately three to seven percent of the United States 
population, and nearly 50% of those affected fail to respond to first-line 
treatment regimens, such as medication and/or therapy (Boland et al., 
2018). Failed treatment can be influenced by environment exposures, 








• In treating anxiety, do those who elect to have 
pharmacogenomic testing versus those who are treated based 
on first-line treatments have better symptom management?
– Combination therapy provided no additional benefit
• Patients often refuse
– Only 50.6% of patients remain on first-line provider preference 
after pharmacogenetic testing was completed (Boland et al., 
2018).
– Genetic variation plays a major role in medication metabolism
• Those with SLC6A4 and MTHFR genotype do not metabolize 
traditional first-line SSRI and SNRI medications (Boland et 
al., 2018). Therefore, would fail many first-line medication 
trials.
– Bradley et al. (2018), also showed promising statistical benefits 
of pharmacogenetic testing.
• Patients classified to have moderate to severe anxiety showed 
a reduction in anxiety symptoms when they were prescribed 
medications based off NeuroIdgenetix® guided treatment.
• Providers made less changes to medications to those who had 
the genetic testing done in comparison to those who were 
prescribed provider preference medications (Bradley et al., 
2018).
• In managing anxiety, would patients who respond to 
pharmacogenomic testing have decreased healthcare costs and 
improve overall healthcare efficacy in comparison to those who 
trial several medications?
– In comparing healthcare costs of first-line methods versus results 
from pharmacogenetic testing, studies indicate decreased health 
care costs for those who receive pharmacogenetic testing.
– Those who were part of the CALM trial saw an increase in 
healthcare costs of $245 over an 18-month period (Joesch et al., 
2013). These patients received medications based off first-line 
medication treatment and were offered CBT. While those who 
had IDgenetix® pharmacogenetic testing saw a decrease of $535 
in healthcare costs over a three-year period (Najafzaheh et al., 
2017).
– Winner et al. (2013) also supports decreased healthcare costs for 
those who are treated based on pharmacogenetic testing.
• Those who received medication labeled “use with caution and 
frequent monitoring” saw a significant increase in treatment 
costs, more general medical visits, more psychiatric visits, 
increase in disability claims, decreased productivity, and 
missed work (Winner et al., 2013). 
• Those who were treated with “use with caution” or “use as 
directed” medications equally both saw decreased healthcare 
costs and increased healthcare efficacy with decreased medical 
and psychiatric visits. (Winner et al., 2013). 
Anxiety affects approximately three to seven percent of the United 
States population, and nearly 50% of the diagnosed patients fail to 
respond to first-line treatment regimens (Boland, Duffy, & Meyer 
2018). Traditional first-line treatments include medication therapy, 
cognitive behavioral therapy (CBT), or the combination of both. With 
such a high initial failure rate, recent studies indicate promising results 
in managing anxiety with pharmacogenomic testing. 
Pharmacogenomic testing is allowing providers to prescribe 
medication based on individual genetic makeup, focusing on how each 
patient metabolizes certain medications. The purpose of this literature 
review was to determine if first-line methods or pharmacogenomic 
testing provide patients with more prompt symptom relief. Through a 
review of several electronic databases and articles, pharmacogenomic 
testing is yielding promising results in symptom relief, decreasing 
healthcare costs, and increasing healthcare efficacy. Not only is 
pharmacogenomic testing promising for anxiety management, it also 
gives insight to several other medication classes. With this 
information, pharmacogenomic testing may soon be a screening tool in 
future medicine.
Keywords: anxiety, pharmacogenomic testing, anxiety management, 
first-line anxiety treatment, pharmacogenetic testing 
 In treating anxiety, do those who elect to have pharmacogenomic 
testing versus those who are treated based on first-line treatments have 
better symptom management?
 In managing anxiety, would patients who respond to pharmacogenetic 
testing have decreased healthcare costs and improve overall healthcare 
efficacy in comparison to those who trial several medications?
• First-line Treatment for Anxiety
– SSRI medication, CBT, or the combination of both
– Many individuals decline CBT
– 50% of individuals fail first-line treatment methods
• Individual responses vary to treatment making management 
difficult
• Pharmacogenomic Testing in  Managing Anxiety
– Of the 50% of individuals who fail first-line treatment methods, 
50% of those fail due to genetic variation.
– Testing allows providers to prescribe medications based on each 
individual DNA
• Research is focusing on CYP450 gene which is responsible for 
oxidation of antidepressant medications.
• Those with SLC6A4 and MTHFR genotype benefit from 
pharmacogenomic testing, by eliminating drugs that will not 
produce effective metabolism.
• CYP2D6 is commonly found in Caucasians vs African 
Americans leading to different medication regimens
• Cost Comparison in Pharmacogenomic Testing Versus First-line 
Methods
– A trial with IDgenetix® showed a $535 cost saving over a three-
year period in those who elected to have pharmacogenetic 
testing.
– Brown et al., (2017) concluded that those who received 
pharmacogenomic testing saved $3,988 within that testing year
• This was an extension of a trial which concluded $1,036 in 
yearly medical costs
– Winner et al., (2017) trial concluded pharmacogenetic testing can 
lead to decreased direct and indirect healthcare utilization and 
cost 
• Those prescribed medication marked “use with caution with 
more frequent monitoring” had more general medical visits, 
along with more sick days, and more disability claims
Understanding how genetic testing works and implicating those results 
into practice is promising for future medicine. Mills, Voora, Payser, & 
Haga (2013). Since this is a relatively new therapeutic option, 
providers are not familiar with the test’s interpretation (Mills et al., 
2013). Therefore, providers are not offering this option to their 
patients. Integrating pharmacogenetic testing into primary care is the 
most critical specialty as that is where most medications are 
prescribed. 
• Providers should become familiar with the tests interpretation
• Discuss with patients the purpose of the test
– The roles genes play in medication metabolism
• Risk vs Benefit
• Limitations
• Future benefits the test has to offer
– Providers will know how a certain medications will metabolize 
leading to quicker symptom relief for many conditions
– Will also allow for a warning to patients of certain side effects
With more research, it appears pharmacogenetic testing could be 
standard of care as a screening tool not only for anxiety medications 
but for several other health conditions. Once a patient is tested, 
clinicians will know how several different classes of medications work 
based on an individual’s genetic makeup. Thus, reducing the trial and 
error method of medication management, decreasing healthcare costs, 
and increasing healthcare efficacy.
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Statement of the Problem
Underdiagnosis of anxiety is quite common, with an average patient 
seeing 10 healthcare professionals before a definitive diagnosis is made, 
which can lead to increased health care costs in comparison to other 
disorders (Lee, 2018). According to Genome Wide Association Studies 
(GWAS), genetic variation alone accounts for 42% of varied first-line 
therapy response (Boland et al., 2018). Due to a person’s genetic make-
up, patients are not being prescribed the most effective medication given 
their deoxyribonucleic acid (DNA). With such a high initial failure rate, 
pharmacogenomic testing has become an area of research. With this 
research, it is thought patients can experience symptom relief upon initial 
treatment, prevent future relapse, reduce healthcare costs, and improve 
overall healthcare efficacy. 
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